Overview

Pletaal SR Post Marketing Observational Study

Status:
Unknown status
Trial end date:
0000-00-00
Target enrollment:
3000
Participant gender:
Both
Summary
This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Last Updated:
2013-01-31
Criteria
Inclusion Criteria:

- Patients must meet all of the following inclusion criteria to be eligible for enrollment
into the study : 1. Patients who are prescribed Pletaal® SR capsule treatment as per
investigator's medical judgment for adults aged 19 and over.

2. Patients who gave written authorization to use their personal and health data Physician
(Investigator) will refer to the product market authorization (package insert) for
inclusion criteria.

Exclusion Criteria:

- Patients presenting with any of the following will not be included in the study 1.
Patients with hemorrhage 2. Patients with congestive heart failure 3. Patients with
known hypersensitivity to Cilostazole or any ingredients of Pletaal® 4. Women who are
pregnant or may possibly become pregnant 5. Patients who is not eligible to
participate this study as investigator's medical judgment Physician (Investigator)
will refer to the product market authorization (package insert) for exclusion
criteria.